Cardiac AngiosarcomaCAIRNCT06715579
Cardiac Angiosarcoma International Registry
An observational study of Cardiac Angiosarcoma, run by Immune Oncology Research Institute at 1 site in Armenia.
Trial summary
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cardiac Angiosarcoma
- How many people
- 500 participants
- Where
- 1 siteArmenia
- Study dates
- 1 May 2025to May 2035
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients diagnosed with Cardiac Angiosarcoma
Who may be able to join
- Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through histopathological examination, including subtypes such as hemangiosarcoma and epithelioid hemangiosarcoma.
- Diagnosis Timing: Eligible patients must have been diagnosed between January 2015 and January 2035.
- Geographical Representation: Participants should be from diverse geographical locations to ensure a comprehensive understanding of the disease across different populations.
- Treatment Status: Patients who have received any treatment (surgery, chemotherapy, immunotherapy or radiation) for cardiac angiosarcoma may be included to evaluate treatment outcomes.
- Informed Consent: For prospective patients, informed consent must be obtained before they are included in the registry.
- Clinical Data Availability: Relevant clinical data, including demographics, tumor characteristics (size, location), treatment regimens, and outcomes, must be available for analysis.
- Follow-Up Willingness: Participants should be willing to undergo follow-up assessments as part of the registry's data collection efforts.
Who cannot join
- Patients who decline to provide informed consent.
- Cases where cardiac involvement is secondary to another primary malignancy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Armenia1 site, 1 recruiting
- Recruiting
Yeolyan Hematology and Oncology Center
Yerevan, 0014
Amalya Sargsyan, MD, MSc, +374 99999641, amalyasargsyan@gmail.com
Amalya Sargsyan, MD
About this study
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are:
- Collect clinical data, including demographics, medical history, treatments, and outcomes, to build a comprehensive database.
- Analyze data to evaluate and identify genetic, environmental, or lifestyle risk factors for cardiac angiosarcoma.
- Evaluate the effectiveness of various treatments (surgery, chemotherapy, immunotherapy, radiation) to inform best practices.
- Develop evidence-based guidelines and recommendations for prevention, diagnosis, treatment, and management based on registry data.
Read the detailed description
Primary cardiac angiosarcoma arises directly within the heart, unlike secondary cardiac tumors that originate from elsewhere in the body. While it predominantly affects the right side of the heart, particularly the right atrium, it can also impact other cardiac chambers and structures. The characteristic feature of cardiac angiosarcoma is the rapid formation of abnormal blood vessels that invade the myocardium, leading to the destruction of healthy heart tissue.The five-year survival rate for patients with primary cardiac angiosarcoma (PCA) is reported to be around 14%. In contrast, familial variants of this malignancy exhibit even more severe outcomes, with a mean survival rate of only 4 months.
Establishing an international registry for cardiac angiosarcomas is crucial for several reasons:
- The registry will facilitate a comprehensive understanding of the clinical characteristics, treatment responses, and outcomes associated with cardiac angiosarcoma. By collecting data from diverse populations, researchers can identify patterns and factors that influence survival rates. It is crucial to better understand the growth rates and risk factors associated with cardiac angiosarcoma and to make the disease more manageable.
- The international registry will enable the latest advancements in oncology and related medical fields to be incorporated into clinical practice. It will provide a platform for developing and conducting clinical trials aimed at improving treatment strategies and increasing survival rates for patients with cardiac angiosarcoma.
- Finally, with data from various institutions and countries, the registry will promote collaboration among healthcare professionals, researchers, and institutions dedicated to improving outcomes for patients with this rare malignancy.
Creating an international registry for cardiac angiosarcoma is crucial for better understanding this aggressive cancer. It will help address the rising cancer burden and support research and treatment advancements that could improve patient survival rates and prevention.
The following data will be collected through questionnaires:
- Patient characteristics
- Characteristics of Primary Cardiac Angiosarcomas
- Details of the diagnosis and treatment
- Complications and late effects of treatment
- Outcomes and follow-up information
Quality control and data management will be done by the Immune Oncology Research Institute.
- Conditions
- Cardiac Angiosarcoma
- Keywords
- Cardiac Angiosarcoma, Angiosarcoma, Hemangiosarcoma, Epithelioid Hemangiosarcoma, Primary Cardiac Sarcoma
- Medical subject headings
- Hemangiosarcoma
What is being measured
The primary outcome is the main question the study is designed to answer.
6-month overall survival
Measured: 6 months
Secondary outcomes (8)
1-year overall survival
Measured: 1 year
6-month progression free survival
Measured: 6 months
1-year progression free survival
Measured: 1 year
3-year progression free survival
Measured: 3 years
6-month event-free survival
Measured: 6 months
1-year event-free survival
Measured: 1 year
3-year event-free survival
Measured: 3 years
Complete remission rate
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2024
- Study start1 May 2025
- Primary completionMay 2035 (estimated)
- Study completionMay 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac AngiosarcomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Other
- Enrolment
- 500 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Immune Oncology Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Shushan Hovsepyan, MD, Principal investigator, Immune Oncology Research Institute, Yerevan, ArmeniaAmalya Sargsyan, MD, Study chair, Immune Oncology Research Institute, Yerevan, ArmeniaRuzanna Papyan, MD, Study director, Immune Oncology Research Institute, Yerevan, Armenia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06715579
- Sponsor's protocol ID
- IMMONC0020
- Acronym
- CAIR
- Status last verified
- Feb 2026
- First submitted
- 28 Nov 2024
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cardiac Angiosarcoma International Registry
- ClinicalTrials.gov ID
- NCT06715579
- Acronym / sponsor ID
- CAIR / IMMONC0020
- Conditions
- Cardiac Angiosarcoma
- Keywords
- Cardiac Angiosarcoma, Angiosarcoma, Hemangiosarcoma, Epithelioid Hemangiosarcoma, Primary Cardiac Sarcoma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Immune Oncology Research InstituteUniversity, hospital or other
- Study start
- 1 May 2025 (actual)
- Primary completion
- May 2035 (estimated)
- Study completion
- May 2035 (estimated)
- First posted
- 4 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are:
- Collect clinical data, including demographics, medical history, treatments, and outcomes, to build a comprehensive database.
- Analyze data to evaluate and identify genetic, environmental, or lifestyle risk factors for cardiac angiosarcoma.
- Evaluate the effectiveness of various treatments (surgery, chemotherapy, immunotherapy, radiation) to inform best practices.
- Develop evidence-based guidelines and recommendations for prevention, diagnosis, treatment, and management based on registry data.
Detailed description
Primary cardiac angiosarcoma arises directly within the heart, unlike secondary cardiac tumors that originate from elsewhere in the body. While it predominantly affects the right side of the heart, particularly the right atrium, it can also impact other cardiac chambers and structures. The characteristic feature of cardiac angiosarcoma is the rapid formation of abnormal blood vessels that invade the myocardium, leading to the destruction of healthy heart tissue.The five-year survival rate for patients with primary cardiac angiosarcoma (PCA) is reported to be around 14%. In contrast, familial variants of this malignancy exhibit even more severe outcomes, with a mean survival rate of only 4 months.
Establishing an international registry for cardiac angiosarcomas is crucial for several reasons:
- The registry will facilitate a comprehensive understanding of the clinical characteristics, treatment responses, and outcomes associated with cardiac angiosarcoma. By collecting data from diverse populations, researchers can identify patterns and factors that influence survival rates. It is crucial to better understand the growth rates and risk factors associated with cardiac angiosarcoma and to make the disease more manageable.
- The international registry will enable the latest advancements in oncology and related medical fields to be incorporated into clinical practice. It will provide a platform for developing and conducting clinical trials aimed at improving treatment strategies and increasing survival rates for patients with cardiac angiosarcoma.
- Finally, with data from various institutions and countries, the registry will promote collaboration among healthcare professionals, researchers, and institutions dedicated to improving outcomes for patients with this rare malignancy.
Creating an international registry for cardiac angiosarcoma is crucial for better understanding this aggressive cancer. It will help address the rising cancer burden and support research and treatment advancements that could improve patient survival rates and prevention.
The following data will be collected through questionnaires:
- Patient characteristics
- Characteristics of Primary Cardiac Angiosarcomas
- Details of the diagnosis and treatment
- Complications and late effects of treatment
- Outcomes and follow-up information
Quality control and data management will be done by the Immune Oncology Research Institute.
Study design
- Observational model
- Case only
- Time perspective
- Other
- Target follow-up
- 5 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients diagnosed with Cardiac Angiosarcoma
Key inclusion criteria (7 listed)
- Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through histopathological examination, including subtypes such as hemangiosarcoma and epithelioid hemangiosarcoma.
- Diagnosis Timing: Eligible patients must have been diagnosed between January 2015 and January 2035.
- Geographical Representation: Participants should be from diverse geographical locations to ensure a comprehensive understanding of the disease across different populations.
- Treatment Status: Patients who have received any treatment (surgery, chemotherapy, immunotherapy or radiation) for cardiac angiosarcoma may be included to evaluate treatment outcomes.
- Informed Consent: For prospective patients, informed consent must be obtained before they are included in the registry.
Key exclusion criteria (2 listed)
- Patients who decline to provide informed consent.
- Cases where cardiac involvement is secondary to another primary malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
6-month overall survival
Time frame: 6 months
8 secondary outcomes
1-year overall survival
Time frame: 1 year
6-month progression free survival
Time frame: 6 months
1-year progression free survival
Time frame: 1 year
3-year progression free survival
Time frame: 3 years
6-month event-free survival
Time frame: 6 months
1-year event-free survival
Time frame: 1 year
3-year event-free survival
Time frame: 3 years
Complete remission rate
Time frame: 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Shushan Hovsepyan, MD principal investigator
Immune Oncology Research Institute, Yerevan, Armenia
Amalya Sargsyan, MD study chair
Immune Oncology Research Institute, Yerevan, Armenia
Ruzanna Papyan, MD study director
Immune Oncology Research Institute, Yerevan, Armenia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiac Angiosarcoma, run by Immune Oncology Research Institute at 1 site in Armenia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Armenia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aharon Tsaturyan, MD (+374 99190152, aharon3tsaturyan@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
6-month overall survival (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.